贝伐珠单抗联合XELOX化疗治疗结直肠癌患者的效果及对其血清CRP水平的影响

目的:探讨贝伐珠单抗联合XELOX(奥沙利铂+卡培他滨)化疗治疗结直肠癌患者的效果及对其血清CRP(C反应蛋白)水平的影响。方法:选取2018年4月—2020年4月广东省廉江市人民医院收治的86例结直肠癌患者作为研究对象,按照计算机分组法分为对照组和观察组,每组43例。对照组采用XELOX(奥沙利铂+卡培他滨)方案治疗,观察组在对照组治疗基础上结合贝伐珠单抗治疗,每3周重复1次,共化疗3个周期,观察两组治疗效果及血清 CRP水平。结果:观察组治疗有效率为48.84 %(21/43),高于对照组的32.56 % (14/43),差异有统计学意义(P＜0.05)。治疗前观察组和对照组的血清 CRP 水平比较,差异无统计学意义(17.51±3.82 vs 17.38±3.63,P＞0.05),治疗后观察组血清CRP水平明显低于对照组(7.66±0.71 vs 11.56±2.32),差异有统计学意义(P＜0.05)。两组不良反应发生率比较,差异无统计学意义(P＞0.05)。结论:贝伐珠单抗联合XELOX化疗治疗结直肠癌患者可显著改善其炎症水平,提高免疫情况,从而提高治疗效果。

The effect of bevacizumab combined with XELOX chemotherapy in the treatment of patients with colorectal cancer and its effect on serum CRP levels

Objective: To investigate the effect of bevacizumab combined with XELOX chemotherapy in the treatment of patients with colorectal cancer and its effect on serum CRP levels. Methods: From April 2018 to April 2020 in our hospital, 86 patients with colorectal cancer were divided into groups according to the computerized method and divided into control group 43 cases, treated with XELOX (Oxaliplatin and Capecitabine) regimen, 43 cases in observation group combined with Bevac on the basis of control group.There are 3 cycles of chemotherapy in total and repeated every 3 weeks. The treatment effect and serum levels of the two groups were observed for the treatment with lizumab. Results: The effective rate of the experimental group was 48.83 % (21/43), and the total effective rate of the experimental group was 32.56 % (14/43), which was significantly higher than that of the control group (P＜0.05). Before treatment, there was no significant difference in the serum CRP level between the experimental group and the control group (17.51±3.82 vs. 17.38 ± 3.63, P＞0.05). After treatment, the serum CRP level of the experimental group was significantly lower than that of the control group (7.66±0.71 vs. 11.56±2.32, P＜0.05). The data difference was statistically significant, and there was no significant difference in the incidence of adverse reactions between the two groups (P＞0.05). Conclusion: Bevacizumab combined with XELOX chemotherapy in the treatment of colorectal cancer patients can significantly improve the level of inflammation, improve the immune status, so as to improve the treatment effect, and will not significantly increase the adverse reactions.